Cytokinetics

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
564
Market Cap
$6.5B
Website

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

First Posted Date
2021-04-19
Last Posted Date
2024-12-04
Lead Sponsor
Cytokinetics
Target Recruit Count
900
Registration Number
NCT04848506
Locations
πŸ‡ΊπŸ‡Έ

Intermountain Medical Center, Murray, Utah, United States

πŸ‡ͺπŸ‡Έ

Hospital Clinic Barcelona, Barcelona, Spain

πŸ‡ΊπŸ‡Έ

Alaska Heart and Vascular Institute, Anchorage, Alaska, United States

and more 71 locations

Omecamtiv Mecarbil Post-trial Access Study

First Posted Date
2020-07-09
Last Posted Date
2021-07-30
Lead Sponsor
Cytokinetics
Registration Number
NCT04464525

Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM

First Posted Date
2020-01-07
Last Posted Date
2024-01-10
Lead Sponsor
Cytokinetics
Target Recruit Count
96
Registration Number
NCT04219826
Locations
πŸ‡ΊπŸ‡Έ

New York University Langone Health Medical Center, New York, New York, United States

πŸ‡ΊπŸ‡Έ

Washington University School of Medicine, Saint Louis, Missouri, United States

πŸ‡ΊπŸ‡Έ

Intermountain Medical Center, Murray, Utah, United States

and more 19 locations

Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults

First Posted Date
2019-11-25
Last Posted Date
2021-11-04
Lead Sponsor
Cytokinetics
Target Recruit Count
70
Registration Number
NCT04175808
Locations
πŸ‡¬πŸ‡§

Research Site, Leeds, United Kingdom

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

First Posted Date
2018-12-07
Last Posted Date
2020-01-29
Lead Sponsor
Cytokinetics
Target Recruit Count
114
Registration Number
NCT03767855
Locations
πŸ‡ΊπŸ‡Έ

Clinical Site, Tempe, Arizona, United States

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

First Posted Date
2018-11-30
Last Posted Date
2023-03-07
Lead Sponsor
Cytokinetics
Target Recruit Count
276
Registration Number
NCT03759392
Locations
πŸ‡ΊπŸ‡Έ

Alaska Heart and Vascular Institute, Anchorage, Alaska, United States

πŸ‡ΊπŸ‡Έ

Glacier View Research Institute, Cardiology, Kalispell, Montana, United States

πŸ‡¨πŸ‡¦

Mcgill University Health Centre (MUHC)-The Montreal General Hospital (MGH), Montreal, Quebec, Canada

and more 78 locations

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

First Posted Date
2017-05-19
Last Posted Date
2020-09-11
Lead Sponsor
Cytokinetics
Target Recruit Count
458
Registration Number
NCT03160898
Locations
πŸ‡ΊπŸ‡Έ

Washington University School of Medicine, Saint Louis, Missouri, United States

πŸ‡ΊπŸ‡Έ

Neurology Associates, P.C., Lincoln, Nebraska, United States

πŸ‡ΊπŸ‡Έ

West Virginia University, Dept. of Neurology, Morgantown, West Virginia, United States

and more 60 locations

A Study for Patients Who Completed VITALITY-ALS (CY 4031)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2016-10-18
Last Posted Date
2021-06-15
Lead Sponsor
Cytokinetics
Target Recruit Count
280
Registration Number
NCT02936635
Locations
πŸ‡ΊπŸ‡Έ

Cedars-Sinai Medical Center, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Stanford Hospital and Clinics, Stanford, California, United States

πŸ‡ΊπŸ‡Έ

The Emory Clinic, Atlanta, Georgia, United States

and more 64 locations

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

First Posted Date
2016-10-11
Last Posted Date
2021-11-05
Lead Sponsor
Cytokinetics
Target Recruit Count
8256
Registration Number
NCT02929329
Locations
πŸ‡¬πŸ‡§

Research Site, Worcester, United Kingdom

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

First Posted Date
2016-03-01
Last Posted Date
2021-07-27
Lead Sponsor
Cytokinetics
Target Recruit Count
81
Registration Number
NCT02695420
Locations
πŸ‡―πŸ‡΅

Research Site, Shinagawa-ku, Tokyo, Japan

Β© Copyright 2024. All Rights Reserved by MedPath